The Journal of Clinical Endocrinology & Metabolism · 2023 · 46 citations · 47 references
MedicineEndocrinologyOncologyEndocrine OncologyMetastasisNeoplasiaEndocrine Tumor ImagingEndocrine Tumor PathologyEndocrine Tumor PrognosisPheochromocytoma ImagingTumor ImagingTumor MarkersEndocrine Tumor ImmunohistochemistryEndocrine Tumor MetastasisMetastatic Endocrine Tumor PathologyMetastatic Risk AssessmentParaganglioma GeneticsPheochromocytoma GeneticsPheochromocytoma PathologySomatostatin Receptor Expression
CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) with pathogenic mutations in the succinate dehydrogenase subunit B (SDHB) are associated with a high metastatic risk. Somatostatin receptor 2 (SSTR2)-dependent imaging is the most sensitive imaging modality for SDHB-related PPGLs, suggesting that SSTR2 expression is a significant cell surface therapeutic biomarker of such tumors. OBJECTIVE: Exploration of the relationship between SSTR2 immunoreactivity and SDHB immunoreactivity, mutational status, and clinical behavior of PPGLs. Evaluation of SSTR-based therapies in metastatic PPGLs. METHODS: Retrospective analysis of a multicenter cohort of PPGLs at 6 specialized Endocrine Tumor Centers in Germany, The Netherlands, and Switzerland. Patients with PPGLs participating in the ENSAT registry were included. Clinical data were extracted from medical records, and immunohistochemistry (IHC) for SDHB and SSTR2 was performed in patients with available tumor tissue. Immunoreactivity of SSTR2 was investigated using Volante scores. The main outcome measure was the association of SSTR2 IHC positivity with genetic and clinical-pathological features of PPGLs. RESULTS: Of 202 patients with PPGLs, 50% were SSTR2 positive. SSTR2 positivity was significantly associated with SDHB- and SDHx-related PPGLs, with the strongest SSTR2 staining intensity in SDHB-related PPGLs (P = .01). Moreover, SSTR2 expression was significantly associated with metastatic disease independent of SDHB/SDHx mutation status (P < .001). In metastatic PPGLs, the disease control rate with first-line SSTR-based radionuclide therapy was 67% (n = 22, n = 11 SDHx), and with first-line "cold" somatostatin analogs 100% (n = 6, n = 3 SDHx). CONCLUSION: SSTR2 expression was independently associated with SDHB/SDHx mutations and metastatic disease. We confirm a high disease control rate of somatostatin receptor-based therapies in metastatic PPGLs.
47
Sue Richards, Nazneen Aziz, Sherri J. Bale et al. · Genetics in Medicine · 2015 · 32.2K citations · Full text
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations
Medicine, Oncology, Pharmacotherapy +17
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text
Medicine, Endocrinology, Oncology +17
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
Lauren Fishbein, Ignaty Leshchiner, Vonn Walter et al. · Cancer Cell · 2017 · 783 citations · Full text